

**15 December 2009**

## **Silver sulphadiazine (Flamazine) funding approved**

PHARMAC is pleased to announce the approval of a supply agreement with Smith and Nephew Limited for silver sulphadiazine 1% cream (Flamazine).

Smith and Nephew is discontinuing silver sulphadiazine 1% with 0.2% chlorhexidine digluconate (Silvazine) once its remaining stock is depleted (which has nearly occurred).

The listing of Flamazine will ensure that a funded topical antibacterial, used primarily as a topical burn cream on second and third-degree burns, remains available.

### **Summary of the decision**

Flamazine will be fully funded and listed in Section B and Section H of the Pharmaceutical Schedule from 1 January 2010 at a subsidy and price of \$12.30 per 50 g OP (ex-manufacturer, excluding GST).

Flamazine will also be available on PSO for up to 250 g (five tubes).

We note that we had consulted on Flamazine having delisting protection until 1 January 2012; please note that Flamazine will not have delisting protection, and will now be subject to a risk sharing arrangement and a price and subsidy review in 2010.

If you have any queries about this funding decision you can call our toll free number (9 am to 5 pm, Monday to Friday) on 0800 66 00 50.

### **Feedback received**

We appreciate the feedback we received in response to consultation and acknowledge the time people took to respond. Responses were supportive towards the continued listing of a topical antibacterial for burns treatment on the Pharmaceutical Schedule.